Discoid and Subacute Lupus Erythematosus Treated With 0.5% R-Salbutamol Cream

Wulf, Hans Christian; Ullman, S

doi:10.1001/archderm.143.12.1589

Cited by 20 publications

(13 citation statements)

References 5 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The binding of a β -2 receptor agonist to these cells results in stimulation of the receptor and inhibition of expression of inflammatory genes. This prevents the production of proinflammatory cytokines, such as interleukin-2 and interferon- γ [24, 56], and effectively suppresses inflammation. Therefore, the primary effects of salbutamol on the chronic phase of inflammation may be associated with its effects on the β -2 adrenergic receptors located on the monocytes and macrophages that comprise the basic components of chronic inflammation.…”

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory and Antinociceptive Effects of Salbutamol on Acute and Chronic Models of Inflammation in Rats: Involvement of an Antioxidant Mechanism

Uzkeser

Çadırcı

Halıcı

et al. 2012

Mediators of Inflammation

View full text Add to dashboard Cite

The possible role ofβ-2 adrenergic receptors in modulation of inflammatory and nociceptive conditions suggests that theβ-2 adrenergic receptor agonist, salbutamol, may have beneficial anti-inflammatory and analgesic effects. Therefore, in this study, we induced inflammatory and nociceptive responses with carrageenan-induced paw edema or cotton-pellet-induced granuloma models, both of which result in oxidative stress. We hypothesized that salbutamol would prevent inflammatory and nociceptive responses by stimulatingβ-2 adrenergic receptors and the prevention of generation of ROS during the acute inflammation process in rats. Both doses of salbutamol used in the study (1 and 2 mg/kg) effectively blocked the acute inflammation and inflammatory nociception induced by carrageenan. In the cotton-pellet-induced granuloma test, both doses of salbutamol also significantly decreased the weight of granuloma tissue on the cotton pellets when compared to the control. Anti-inflammatory and analgesic effects of salbutamol were found to be comparable with those of indomethacin. Salbutamol decreased myeloperoxidase (MPO) activity and lipid peroxidation (LPO) level and increased the activity of superoxide dismutase (SOD) and level of glutathione (GSH) during the acute phase of inflammation. In conclusion, salbutamol can decrease acute and chronic inflammation, possibly through the stimulation ofβ-2 adrenergic receptors. This anti-inflammatory effect may be of significance in asthma treatment, where inflammation also takes part in the etiopathology. This study reveals that salbutamol has significant antioxidative effects, which at least partially explain its anti-inflammatory capabilities. These findings presented here may also shed light on the roles ofβ-2 adrenergic receptors in inflammatory and hyperalgesic conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory and Antinociceptive Effects of Salbutamol on Acute and Chronic Models of Inflammation in Rats: Involvement of an Antioxidant Mechanism

Uzkeser

Çadırcı

Halıcı

et al. 2012

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…12 Patients were asked to apply 0AE5% R-salbutamol cream on their skin lesions twice daily. After initial improvement in SCLE, two patients developed toxic eczema after 6-8 weeks, which disappeared under topical corticosteroids within 4-6 days.…”

Section: Discussionmentioning

confidence: 99%

A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus

Jemec

Ullman

Goodfield

et al. 2009

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Topical R-salbutamol sulfate Inhibits IL-2 and interferon-¡ production by T-cells [89] Oral Polypodium leucotomos Inhibits keratinocyte apoptosis induced by ultraviolet radiation [17] Lenalidomide Inhibits cytokines including TNF-a, IL-1b, 6, 12 [62,63] Apremilast Phosphodiesterase 4 inhibitor [78] Biologics Rituximab Chimeric monoclonal antibody that induces B-cell destruction [64] Belimumab Human monoclonal antibody that decreases B-cell survival and production of autoantibodies [73] Ustekinumab Human monoclonal antibody that blocks IL-12 and 23 [90] Epratuzumab Humanized anti-CD22 monoclonal antibody that inhibits B-cell receptor signaling [79,80] Sifalimumab Blocks interferon-a [82] Other UVA-1 phototherapy Unknown. Possible apoptosis of resident T cells, inhibition of antigen presentation or inhibition of TNF-a production [60] Sairei-to Japanese-Chinese herbal medicine that may suppress B-cell function [91] C. B. Hansen & J. P. Callen doses of dapsone range from 25 to 150 mg a day.…”

Section: Treatmentmentioning

confidence: 99%